{"gene":"ETFDH","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2007,"finding":"ETF-QO (ETFDH) contains a single [4Fe-4S]2+,1+ cluster and one equivalent of FAD. Site-directed mutagenesis of residues Y501 and T525 (equivalent to Y533 and T558 in porcine ETF-QO) near the iron-sulfur cluster demonstrated that these residues are within hydrogen-bonding distance of cysteine ligands. Single mutations Y501F and T525A decreased the midpoint potential of the iron-sulfur cluster from +37 mV (wild-type) to -60 mV, and the double mutant Y501F/T525A to -128 mV. Lowering the midpoint potential decreased steady-state ubiquinone reductase activity and ETF semiquinone disproportionation, demonstrating that reduction of the iron-sulfur cluster is required for catalytic activity.","method":"Site-directed mutagenesis, potentiometric titrations monitored by CW EPR, steady-state ubiquinone reductase activity assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with site-directed mutagenesis and multiple orthogonal assays (EPR, potentiometry, activity) in a single rigorous study","pmids":["18069858"],"is_preprint":false},{"year":2007,"finding":"Electron spin relaxation enhancement measurements established that the point-dipole interspin distance between the [4Fe-4S]+ cluster and the FAD semiquinone in ETF-QO is 18.6 ± 1 Å in human, porcine, and Rhodobacter sphaeroides ETF-QO, consistent with the value calculated from the crystal structure of porcine ETF-QO, confirming proximity of the two redox cofactors within the enzyme.","method":"Electron spin relaxation enhancement (inversion recovery EPR) on redox-poised proteins; comparison with crystal structure distances","journal":"Journal of magnetic resonance","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative distance measurement by EPR relaxation enhancement validated against crystal structure, performed across three species independently","pmids":["18037314"],"is_preprint":false},{"year":2007,"finding":"Mutations in ETFDH cause a secondary deficiency of coenzyme Q10 (CoQ10) in skeletal muscle. Patients with ETFDH mutations showed severely decreased respiratory chain complex I and II+III activities and significantly reduced muscle CoQ10, establishing that ETFDH deficiency leads to secondary CoQ10 deficiency and that late-onset glutaric aciduria type II and myopathic CoQ10 deficiency are allelic disorders.","method":"Biochemical measurement of CoQ10 and respiratory chain complexes in muscle homogenates; ETFDH gene sequencing; tandem mass spectrometry","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical measurements in patient muscle with genetic confirmation, single cohort study","pmids":["17412732"],"is_preprint":false},{"year":2007,"finding":"Mutations in ETFDH (encoding ETF:QO) cause riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency (RR-MADD). In one patient, ETF:QO mutations were associated with riboflavin-sensitive impairment of ETF:QO activity, and partial deficiencies of flavin-dependent acyl-CoA dehydrogenases and respiratory chain complexes were restored to control levels after riboflavin treatment, indicating that FAD cofactor availability modulates ETF:QO function.","method":"ETF:QO enzyme activity assay before and after riboflavin treatment; biochemical analysis of acyl-CoA dehydrogenase and respiratory chain complex activities; ETFDH sequencing","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzyme activity measurements with treatment intervention, single patient with biochemical follow-up","pmids":["17584774"],"is_preprint":false},{"year":2012,"finding":"Riboflavin responsiveness in MADD patients with ETF-QO variants is mechanistically explained by a chaperone effect of FAD/riboflavin on variant ETF-QO folding. Variant ETF-QO proteins associated with RR-MADD showed milder folding defects correctable by riboflavin, while non-responsive variants caused severe misfolding. Variant ETF-QO proteins showed prolonged association with the Hsp60 chaperonin in the mitochondrial matrix, and increased cellular peroxide production, indicating that structurally defective ETF-QO leaks electrons and generates reactive oxygen species.","method":"HEK-293 cell expression system; steady-state protein level analysis; ETF-QO activity assay; thermal stability measurements; cellular peroxide production assay; Hsp60 co-immunoprecipitation","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (activity assay, thermal stability, co-IP with chaperone, ROS measurement) in a single study with patient-variant correlation","pmids":["22611163"],"is_preprint":false},{"year":2013,"finding":"The ETFDH c.158A>G variant causes exon skipping rather than a missense substitution. RNA pull-down of nuclear proteins showed that the variant increases the strength of a preexisting exonic splicing silencer (ESS) motif UAGGGA, which binds inhibitory hnRNP A1, hnRNP A2/B1, and hnRNP H proteins, preventing binding of positive splicing regulators SRSF1 and SRSF5 to overlapping exonic splicing enhancer elements, thereby causing exon 2 skipping and ETFDH protein degradation.","method":"Splicing reporter minigenes; RNA pull-down with nuclear proteins; patient sample mRNA analysis; protein identification of binding partners","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — minigene functional assay plus RNA pull-down identifying specific protein-RNA interactions, mechanistically explaining splicing outcome","pmids":["24123825"],"is_preprint":false},{"year":2018,"finding":"FAD homeostasis disturbance is a crucial pathomechanism of RR-MADD. In Etfdh knock-in mice (carrying the p.A84T mutation) subjected to high-fat, riboflavin-deficient diet, both ETF:QO protein and FAD concentrations were significantly decreased in tissues. After riboflavin treatment, ETF:QO protein increased in proportion to elevated FAD concentrations but not to mRNA levels, demonstrating that riboflavin stabilizes variant ETF:QO protein post-translationally by rebuilding FAD homeostasis.","method":"Etfdh knock-in mouse model; FAD concentration measurements; Western blot; mRNA quantification; patient fibroblast validation","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knock-in mouse model with biochemical and molecular readouts, confirmed in patient fibroblasts, multiple orthogonal methods","pmids":["30232818"],"is_preprint":false},{"year":1999,"finding":"ETF-QO (ETFDH gene product) is a nuclear-encoded protein located in the inner mitochondrial membrane. The ETF-QO gene was mapped to human chromosome 4q33 by somatic cell hybridization and fluorescence in situ hybridization.","method":"Fluorescence in situ hybridization (FISH); somatic cell hybridization","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal cytogenetic methods for chromosomal localization, single study","pmids":["10444348"],"is_preprint":false},{"year":2019,"finding":"ETFDH c.250G>A and c.92C>T mutations in ETF-QO uncouple fatty acid β-oxidation from mitochondrial bioenergetics, resulting in decreased ATP synthesis, dissipated mitochondrial membrane potentials, reduced mitochondrial bioenergetics, and increased neutral lipid droplets and lipid peroxides in MADD patient-derived lymphoblastoid cells. Riboflavin and/or coenzyme Q10 supplementation rescued cells from lipid droplet accumulation.","method":"Patient-derived lymphoblastoid cells; ATP synthesis assay; mitochondrial membrane potential measurement; lipid droplet quantification; lipid peroxide assay; pharmacological rescue with riboflavin/CoQ10","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple bioenergetic readouts in patient-derived cells with pharmacological rescue, single lab study","pmids":["30709034"],"is_preprint":false},{"year":2017,"finding":"ETFDH p.Ala84Thr mutation increases ROS production and causes neurite shortening in cells expressing the mutant protein. Suberic acid (an accumulated intermediate metabolite in MADD) significantly impairs neurite outgrowth of NSC34 cells. Supplementation with carnitine, riboflavin, or CoQ10 restores neurite length, suggesting that ETF-QO dysfunction causes neuronal defects mediated by metabolic intermediates and oxidative stress.","method":"Cell expression system (ETFDH wild-type vs. mutant); ROS production assay; neurite length measurement; pharmacological rescue","journal":"Muscle & nerve","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular model with multiple readouts (ROS, neurite length) and pharmacological rescue, single lab","pmids":["27935074"],"is_preprint":false},{"year":2022,"finding":"A novel ETFDH c.725C>T (p.T242I) mutation enhances degradation of ETF-QO via the ubiquitin proteasome pathway. Five E3 ubiquitin ligases (STUB1, RNF40, UBE3C, CUL3, and CUL1) and one ubiquitin modification site (Cysteine C101) on ETF-QO were identified.","method":"Molecular analysis of ETFDH variant; ubiquitin proteasome pathway assay; identification of E3 ligases and ubiquitination site","journal":"Clinica chimica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — identified ubiquitin pathway and specific E3 ligases/modification site, but single lab with limited replication","pmids":["35314173"],"is_preprint":false},{"year":2024,"finding":"ETFDH p.Ala84Thr mutation activates the BCL-2/mitochondrial outer membrane permeabilization/apoptosis pathway in NSC-34 cells, as shown by elevated levels of BAX, PUMA, cytochrome c, caspase-3, and caspase-9. CoQ10 treatment downregulated these proapoptotic proteins and mitigated neurite growth defects.","method":"NSC-34 cell expression model; Western blot for BCL-2 family proteins; cytochrome c and caspase activity measurement; neurite length assay; pharmacological rescue with CoQ10","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple protein markers of apoptosis pathway quantified with pharmacological rescue, single lab","pmids":["39455656"],"is_preprint":false},{"year":2013,"finding":"Elevated muscle CoQ10 in riboflavin-responsive MADD patients with ETFDH mutations is not due to primary CoQ10 biosynthesis dysregulation but rather secondary to mitochondrial mass proliferation. When CoQ10 levels were normalized to citrate synthase (a mitochondrial mass marker), there was no significant difference from controls. Increased mitochondrial DNA copy number confirmed mitochondrial proliferation. PPARα and lipid metabolism genes were upregulated.","method":"HPLC measurement of CoQ10 in muscle; citrate synthase normalization; mitochondrial DNA copy number quantification; CoQ10 biosynthesis gene expression analysis; PPARα expression","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical methods in a large patient cohort (34 patients), single lab","pmids":["23628458"],"is_preprint":false},{"year":2020,"finding":"ETFDH c.579A>G, a synonymous variant, causes exon 5 skipping. Transcript analysis in vivo and minigene splice assay in vitro confirmed that this synonymous change disrupts normal ETFDH mRNA splicing, leading to production of a truncated protein.","method":"In vivo transcript analysis; in vitro minigene splice assay; RT-PCR","journal":"Frontiers in pediatrics","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — functional splicing confirmed by two orthogonal methods (in vivo and in vitro minigene), single lab","pmids":["32292771"],"is_preprint":false},{"year":2025,"finding":"ETFDH c.487+2T>A mutation leads to mRNA degradation through nonsense-mediated decay (NMD), confirmed by minigene splice assay and RT-PCR. Downregulation of ETFDH in cell experiments led to lipid accumulation, enhanced oxidative stress, and upregulation of ZNF267 expression, suggesting ETFDH is a key regulatory gene in lipid homeostasis and potentially in polycystic kidney development.","method":"Minigene splice assay; RT-PCR; in vitro cell knockdown experiments; lipid accumulation assay; oxidative stress measurement; ZNF267 expression analysis","journal":"Orphanet journal of rare diseases","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — NMD mechanism confirmed by two orthogonal methods, downstream cellular consequences assessed in vitro, single lab","pmids":["40075430"],"is_preprint":false},{"year":2026,"finding":"ETFDH c.1049G>A causes predominant exon 9 skipping resulting in an in-frame 48-amino acid deletion within the FAD-binding domain, confirmed by patient-derived iPSCs and minigene assays. Structural modeling based on the human ETFDH crystal structure showed this deletion disrupts the stabilizing interaction between Arg364 and Glu246, predicting compromised FAD binding. Western blot showed markedly reduced ETFDH protein levels (<10%) in patient cells.","method":"iPSC-derived patient cells; minigene splice assay; RT-PCR; structural modeling based on crystal structure; Western blot","journal":"Orphanet journal of rare diseases","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — splicing confirmed by two orthogonal functional methods with structural modeling validation, single lab","pmids":["42216180"],"is_preprint":false},{"year":2018,"finding":"A splice site ETFDH mutation (c.1285+1G>A, intron 10) alters ETFDH RNA splicing as confirmed by RT-PCR, leading to production of a truncated protein. In silico structural analysis showed the associated missense mutation (c.560C>T) causes instability and loss of protein activation, while the splice variant induces a dramatic conformational change. Patients with at least one missense mutation in the FAD-binding domain may respond to riboflavin or carnitine due to recovery of some enzymatic activity.","method":"RT-PCR for splicing analysis; in silico 3D structural prediction of ETF-QO","journal":"Lipids in health and disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — RT-PCR splicing confirmation is solid but structural conclusions rely solely on in silico modeling, single case","pmids":["30424791"],"is_preprint":false},{"year":2026,"finding":"In Drosophila CRISPR knock-in models carrying patient-relevant Etf-QO missense mutations in FAD- and ubiquinone-binding domains, defective Etf-QO activity disrupts electron flow, promotes ROS production, impairs fatty acid β-oxidation, causes lipid droplet accumulation in skeletal muscle and cardiac tissue, reduces mitochondrial oxygen consumption, and leads to metabolic cardiomyopathy. Activation of AMPK, PGC-1α, and Tfam indicates compensatory mitochondrial biogenesis in response to energy stress.","method":"CRISPR/Cas9 Drosophila knock-in models; locomotor assays; cardiac functional analysis; lipid droplet quantification; in vivo respirometry; ROS measurement; ATP quantification; Western blot for energy stress markers","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR in vivo model with multiple orthogonal functional readouts, preprint not yet peer-reviewed","pmids":["42239388"],"is_preprint":true},{"year":2024,"finding":"ETFDH downregulation in cancer cells (NALM-6 acute lymphoblastic leukemia) limits flexibility of OXPHOS fuel utilization but paradoxically increases cancer cell bioenergetics and accelerates neoplastic growth by activation of the mTORC1/BCL-6/4E-BP1 signaling axis.","method":"ETFDH knockdown/knockout in cancer cell lines; bioenergetic profiling; mTORC1/BCL-6/4E-BP1 signaling pathway analysis","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, mechanistic pathway activation described but limited methodological detail in abstract","pmids":["bio_10.1101_2024.10.25.620155"],"is_preprint":true}],"current_model":"ETFDH encodes ETF-ubiquinone oxidoreductase (ETF-QO), an inner mitochondrial membrane iron-sulfur flavoprotein that accepts electrons from ETF (and thus from multiple acyl-CoA dehydrogenases involved in fatty acid, amino acid, and choline catabolism) and reduces ubiquinone in the respiratory chain via sequential electron transfer through its [4Fe-4S]2+/1+ cluster (whose midpoint potential is essential for activity) and FAD cofactor, which are positioned ~18.6 Å apart; pathogenic ETFDH mutations impair FAD binding and protein folding (correctable by riboflavin acting as a pharmacological chaperone by restoring FAD homeostasis), cause secondary ROS production, activate apoptotic BCL-2 pathways, and lead to secondary CoQ10 deficiency and lipid accumulation, manifesting as multiple acyl-CoA dehydrogenase deficiency (MADD/glutaric aciduria type II)."},"narrative":{"mechanistic_narrative":"ETFDH encodes ETF-ubiquinone oxidoreductase (ETF-QO), a nuclear-encoded iron-sulfur flavoprotein of the inner mitochondrial membrane that channels electrons from electron-transfer flavoprotein into the respiratory chain by reducing ubiquinone, thereby linking fatty acid β-oxidation to mitochondrial bioenergetics [PMID:10444348, PMID:30709034]. Catalysis proceeds by sequential electron transfer through a single [4Fe-4S] cluster and an FAD cofactor positioned ~18.6 Å apart, and reduction of the iron-sulfur cluster is obligatory for ubiquinone reductase activity: lowering its midpoint potential through mutation of cluster-proximal residues impairs both ubiquinone reduction and ETF semiquinone disproportionation [PMID:18069858, PMID:18037314]. Pathogenic ETFDH mutations destabilize the protein and compromise FAD binding, with riboflavin acting as a pharmacological chaperone that post-translationally stabilizes variant ETF-QO by restoring FAD homeostasis rather than altering transcript levels [PMID:22611163, PMID:30232818, PMID:42216180]. Defective ETF-QO uncouples β-oxidation from ATP synthesis, producing reactive oxygen species, lipid droplet accumulation, secondary CoQ10 deficiency, and activation of BCL-2/mitochondrial apoptotic signaling, the molecular basis of multiple acyl-CoA dehydrogenase deficiency (MADD/glutaric aciduria type II) [PMID:17412732, PMID:30709034, PMID:39455656]. A substantial fraction of disease alleles act not as simple missense changes but by disrupting splicing — strengthening exonic silencers, causing exon skipping, or triggering nonsense-mediated decay — and unstable variants are additionally cleared through the ubiquitin-proteasome pathway [PMID:24123825, PMID:35314173, PMID:40075430].","teleology":[{"year":1999,"claim":"Establishing that ETF-QO is a nuclear-encoded inner mitochondrial membrane protein and mapping its gene provided the genetic and subcellular framework for all subsequent disease and mechanistic work.","evidence":"FISH and somatic cell hybridization localizing ETFDH to chromosome 4q33","pmids":["10444348"],"confidence":"Medium","gaps":["Did not address catalytic mechanism or cofactor content","No functional characterization of the protein"]},{"year":2007,"claim":"Quantifying the geometry of the two redox cofactors and demonstrating that iron-sulfur cluster reduction is required for catalysis defined the electron-transfer mechanism of ETF-QO.","evidence":"EPR relaxation-enhancement interspin distance measurement across three species plus site-directed mutagenesis with potentiometric and activity assays","pmids":["18037314","18069858"],"confidence":"High","gaps":["Mutated residues are model probes, not necessarily disease alleles","Did not resolve how ETF docks and delivers electrons"]},{"year":2007,"claim":"Linking ETFDH mutations to secondary CoQ10 deficiency and riboflavin-responsive MADD connected enzyme dysfunction to defined clinical metabolic phenotypes and a treatment.","evidence":"Patient muscle biochemistry, respiratory chain and ETF-QO activity assays before/after riboflavin, with ETFDH sequencing","pmids":["17412732","17584774"],"confidence":"Medium","gaps":["Mechanism of riboflavin responsiveness unresolved at this stage","Single-cohort/single-patient observations"]},{"year":2012,"claim":"Showing that RR-MADD variants are folding-defective and stabilized by FAD/riboflavin established a chaperone mechanism for riboflavin therapy and connected misfolding to ROS leakage.","evidence":"HEK-293 expression of variants with thermal stability, activity, Hsp60 co-IP, and cellular peroxide assays","pmids":["22611163"],"confidence":"High","gaps":["Hsp60 association shown by co-IP without reciprocal/structural validation","Did not quantify FAD occupancy directly"]},{"year":2018,"claim":"Demonstrating in vivo that riboflavin raises variant ETF-QO protein in proportion to FAD but not mRNA confirmed FAD homeostasis as the post-translational basis of riboflavin rescue.","evidence":"Etfdh p.A84T knock-in mouse on high-fat/riboflavin-deficient diet with FAD measurement, Western blot, mRNA quantification, and patient fibroblast validation","pmids":["30232818"],"confidence":"High","gaps":["Single mutation knock-in","Did not map FAD-binding kinetics of individual variants"]},{"year":2019,"claim":"Defining how ETF-QO mutations uncouple β-oxidation from bioenergetics and drive lipid accumulation clarified the downstream cellular pathology of MADD and the basis for CoQ10 supplementation.","evidence":"Patient lymphoblastoid cells with ATP synthesis, membrane potential, lipid droplet and peroxide assays plus riboflavin/CoQ10 rescue","pmids":["30709034"],"confidence":"Medium","gaps":["Lymphoblastoid model not tissue-specific","Did not separate direct enzyme loss from secondary CoQ10 deficiency"]},{"year":2024,"claim":"Identifying activation of the BCL-2/MOMP apoptotic cascade in mutant-expressing neuronal cells linked ETF-QO dysfunction to a defined cell-death program reversible by CoQ10.","evidence":"NSC-34 expression model with Western blot for BAX/PUMA/cytochrome c/caspases, ROS and neurite assays with CoQ10 rescue","pmids":["39455656","27935074"],"confidence":"Medium","gaps":["Overexpression model in a single neuronal line","Causal ordering of ROS, apoptosis, and metabolite toxicity not established"]},{"year":2022,"claim":"Characterizing splicing-disrupting and proteasome-degraded alleles revealed that ETFDH disease is frequently driven by transcript and protein turnover defects rather than missense catalytic loss alone.","evidence":"Minigene splice assays, RNA pull-down identifying hnRNP/SRSF regulators, RT-PCR, NMD analysis, and ubiquitin-proteasome assays identifying E3 ligases and a ubiquitination site","pmids":["24123825","32292771","35314173","40075430"],"confidence":"Medium","gaps":["E3 ligase set identified in a single study without in vivo validation","ZNF267/polycystic kidney link is correlative"]},{"year":2026,"claim":"Structure-guided modeling of an in-frame FAD-domain deletion and in vivo Drosophila knock-in models connected specific structural lesions to FAD-binding loss, cardiac and muscle lipid pathology, and compensatory mitochondrial biogenesis.","evidence":"Patient iPSCs with minigene/RT-PCR and crystal-structure-based modeling; CRISPR Drosophila knock-ins with respirometry, lipid, ROS and energy-stress marker assays (one preprint)","pmids":["42216180","42239388"],"confidence":"Medium","gaps":["Drosophila findings are a non-peer-reviewed preprint","Structural consequence of the deletion is modeled, not experimentally resolved"]},{"year":null,"claim":"A high-resolution structure of human ETF-QO in complex with ETF and ubiquinone, and a unified model relating individual variant cofactor occupancy to clinical riboflavin responsiveness, remain to be established.","evidence":"","pmids":[],"confidence":"Low","gaps":["No experimental human ETF-QO/ETF complex structure in the corpus","No systematic variant-by-variant FAD-occupancy/responsiveness map"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[7,6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,2]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3]}],"complexes":[],"partners":["ETF","HSP60","STUB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16134","full_name":"Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial","aliases":["Electron-transferring-flavoprotein dehydrogenase","ETF dehydrogenase"],"length_aa":617,"mass_kda":68.5,"function":"Accepts electrons from ETF and reduces ubiquinone","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/Q16134/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ETFDH","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ETFDH","total_profiled":1310},"omim":[{"mim_id":"608053","title":"ELECTRON TRANSFER FLAVOPROTEIN, ALPHA POLYPEPTIDE; ETFA","url":"https://www.omim.org/entry/608053"},{"mim_id":"607426","title":"COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1","url":"https://www.omim.org/entry/607426"},{"mim_id":"231680","title":"MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD","url":"https://www.omim.org/entry/231680"},{"mim_id":"231675","title":"ELECTRON TRANSFER FLAVOPROTEIN DEHYDROGENASE; ETFDH","url":"https://www.omim.org/entry/231675"},{"mim_id":"130410","title":"ELECTRON TRANSFER FLAVOPROTEIN, BETA POLYPEPTIDE; ETFB","url":"https://www.omim.org/entry/130410"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":148.9},{"tissue":"tongue","ntpm":162.8}],"url":"https://www.proteinatlas.org/search/ETFDH"},"hgnc":{"alias_symbol":["ETFQO"],"prev_symbol":[]},"alphafold":{"accession":"Q16134","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16134","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16134-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16134-F1-predicted_aligned_error_v6.png","plddt_mean":93.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ETFDH","jax_strain_url":"https://www.jax.org/strain/search?query=ETFDH"},"sequence":{"accession":"Q16134","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16134.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16134/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16134"}},"corpus_meta":[{"pmid":"17412732","id":"PMC_17412732","title":"The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene.","date":"2007","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17412732","citation_count":242,"is_preprint":false},{"pmid":"17584774","id":"PMC_17584774","title":"ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.","date":"2007","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17584774","citation_count":240,"is_preprint":false},{"pmid":"12815589","id":"PMC_12815589","title":"Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12815589","citation_count":191,"is_preprint":false},{"pmid":"19249206","id":"PMC_19249206","title":"ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2009","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/19249206","citation_count":114,"is_preprint":false},{"pmid":"19758981","id":"PMC_19758981","title":"Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations.","date":"2009","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19758981","citation_count":92,"is_preprint":false},{"pmid":"21347544","id":"PMC_21347544","title":"Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/21347544","citation_count":81,"is_preprint":false},{"pmid":"22611163","id":"PMC_22611163","title":"Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22611163","citation_count":78,"is_preprint":false},{"pmid":"24357026","id":"PMC_24357026","title":"Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency.","date":"2013","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/24357026","citation_count":76,"is_preprint":false},{"pmid":"20370797","id":"PMC_20370797","title":"High frequency of ETFDH c.250G>A mutation in Taiwanese patients with late-onset lipid storage myopathy.","date":"2010","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20370797","citation_count":52,"is_preprint":false},{"pmid":"19265687","id":"PMC_19265687","title":"Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2009","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19265687","citation_count":44,"is_preprint":false},{"pmid":"20138856","id":"PMC_20138856","title":"High resolution melting analysis facilitates mutation screening of ETFDH gene: applications in riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20138856","citation_count":35,"is_preprint":false},{"pmid":"28456887","id":"PMC_28456887","title":"Heterogeneous Phenotypes in Lipid Storage Myopathy Due to ETFDH Gene Mutations.","date":"2017","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/28456887","citation_count":33,"is_preprint":false},{"pmid":"30424791","id":"PMC_30424791","title":"Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/30424791","citation_count":32,"is_preprint":false},{"pmid":"18069858","id":"PMC_18069858","title":"Impact of mutations on the midpoint potential of the [4Fe-4S]+1,+2 cluster and on catalytic activity in electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO).","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18069858","citation_count":32,"is_preprint":false},{"pmid":"15669683","id":"PMC_15669683","title":"Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency.","date":"2004","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/15669683","citation_count":31,"is_preprint":false},{"pmid":"30232818","id":"PMC_30232818","title":"ETFDH Mutations and Flavin Adenine Dinucleotide Homeostasis Disturbance Are Essential for Developing Riboflavin-Responsive Multiple Acyl-Coenzyme A Dehydrogenation Deficiency.","date":"2018","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30232818","citation_count":29,"is_preprint":false},{"pmid":"27000805","id":"PMC_27000805","title":"Significant clinical heterogeneity with similar ETFDH genotype in three Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency.","date":"2016","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/27000805","citation_count":29,"is_preprint":false},{"pmid":"24123825","id":"PMC_24123825","title":"The ETFDH c.158A>G variation disrupts the balanced interplay of ESE- and ESS-binding proteins thereby causing missplicing and multiple Acyl-CoA dehydrogenation deficiency.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24123825","citation_count":28,"is_preprint":false},{"pmid":"22013910","id":"PMC_22013910","title":"Computational analysis of a novel mutation in ETFDH gene highlights its long-range effects on the FAD-binding motif.","date":"2011","source":"BMC structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/22013910","citation_count":27,"is_preprint":false},{"pmid":"23628458","id":"PMC_23628458","title":"Increased muscle coenzyme Q10 in riboflavin responsive MADD with ETFDH gene mutations due to secondary mitochondrial proliferation.","date":"2013","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23628458","citation_count":26,"is_preprint":false},{"pmid":"29988809","id":"PMC_29988809","title":"Novel ETFDH mutations in four cases of riboflavin responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2018","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/29988809","citation_count":24,"is_preprint":false},{"pmid":"31852447","id":"PMC_31852447","title":"Late-onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (MADD): case reports and epidemiology of ETFDH gene mutations.","date":"2019","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31852447","citation_count":24,"is_preprint":false},{"pmid":"25913573","id":"PMC_25913573","title":"A case of late-onset riboflavin responsive multiple acyl-CoA dehydrogenase deficiency (MADD) with a novel mutation in ETFDH gene.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25913573","citation_count":21,"is_preprint":false},{"pmid":"29249369","id":"PMC_29249369","title":"A novel mutation in ETFDH manifesting as severe neonatal-onset multiple acyl-CoA dehydrogenase deficiency.","date":"2017","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29249369","citation_count":18,"is_preprint":false},{"pmid":"29615056","id":"PMC_29615056","title":"Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy: a case report.","date":"2018","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29615056","citation_count":18,"is_preprint":false},{"pmid":"30709034","id":"PMC_30709034","title":"ETF-QO Mutants Uncoupled Fatty Acid β-Oxidation and Mitochondrial Bioenergetics Leading to Lipid Pathology.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30709034","citation_count":17,"is_preprint":false},{"pmid":"23893693","id":"PMC_23893693","title":"Novel ETFDH mutation and imaging findings in an adult with glutaric aciduria type II.","date":"2014","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/23893693","citation_count":17,"is_preprint":false},{"pmid":"31704152","id":"PMC_31704152","title":"Expression and significance of ETFDH in hepatocellular carcinoma.","date":"2019","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/31704152","citation_count":14,"is_preprint":false},{"pmid":"32393189","id":"PMC_32393189","title":"A novel electron transfer flavoprotein dehydrogenase (ETFDH) gene mutation identified in a newborn with glutaric acidemia type II: a case report of a Chinese family.","date":"2020","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32393189","citation_count":13,"is_preprint":false},{"pmid":"18037314","id":"PMC_18037314","title":"Electron spin relaxation enhancement measurements of interspin distances in human, porcine, and Rhodobacter electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO).","date":"2007","source":"Journal of magnetic resonance (San Diego, Calif. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/18037314","citation_count":13,"is_preprint":false},{"pmid":"32925727","id":"PMC_32925727","title":"Neonatal-onset multiple acyl-CoA dehydrogenase deficiency (MADD) in the ETFDH gene: A case report and a literature review.","date":"2020","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32925727","citation_count":11,"is_preprint":false},{"pmid":"27935074","id":"PMC_27935074","title":"Neurite growth could be impaired by ETFDH mutation but restored by mitochondrial cofactors.","date":"2017","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/27935074","citation_count":11,"is_preprint":false},{"pmid":"31058673","id":"PMC_31058673","title":"Rhabdomyolysis and respiratory insufficiency due to the common ETFDH mutation of c.250G>A in two patients with late-onset multiple acyl-CoA dehydrogenase deficiency.","date":"2019","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31058673","citation_count":11,"is_preprint":false},{"pmid":"21616504","id":"PMC_21616504","title":"Multiple acyl-CoA-dehydrogenase deficiency (MADD)--a novel mutation of electron-transferring-flavoprotein dehydrogenase ETFDH.","date":"2011","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21616504","citation_count":11,"is_preprint":false},{"pmid":"38228875","id":"PMC_38228875","title":"A comparative study on riboflavin responsive multiple acyl-CoA dehydrogenation deficiency due to variants in FLAD1 and ETFDH gene.","date":"2024","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38228875","citation_count":8,"is_preprint":false},{"pmid":"32499892","id":"PMC_32499892","title":"Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients.","date":"2020","source":"European journal of translational myology","url":"https://pubmed.ncbi.nlm.nih.gov/32499892","citation_count":7,"is_preprint":false},{"pmid":"33000234","id":"PMC_33000234","title":"Clinical characteristics and gene mutation analysis of an adult patient with ETFDH‑related multiple acyl‑CoA dehydrogenase deficiency.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33000234","citation_count":6,"is_preprint":false},{"pmid":"32292771","id":"PMC_32292771","title":"A Synonymous Variant c.579A>G in the ETFDH Gene Caused Exon Skipping in a Patient With Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency: A Case Report.","date":"2020","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32292771","citation_count":6,"is_preprint":false},{"pmid":"28914566","id":"PMC_28914566","title":"A novel ETFDH mutation in an adult patient with late-onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2017","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28914566","citation_count":6,"is_preprint":false},{"pmid":"30508893","id":"PMC_30508893","title":"Long-term outcomes of a patient with late-onset multiple acyl-CoA dehydrogenase deficiency caused by novel mutations in ETFDH: A case report.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30508893","citation_count":6,"is_preprint":false},{"pmid":"34066864","id":"PMC_34066864","title":"Characterization of ETFDH and PHGDH Mutations in a Patient with Mild Glutaric Aciduria Type II and Serine Deficiency.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34066864","citation_count":5,"is_preprint":false},{"pmid":"35314173","id":"PMC_35314173","title":"Novel variant of ETFDH leading to multiple acyl-CoA dehydrogenase deficiency by promoting protein degradation via ubiquitin proteasome pathway.","date":"2022","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35314173","citation_count":5,"is_preprint":false},{"pmid":"30022752","id":"PMC_30022752","title":"[A novel mutation in the ETFDH gene of an infant with multiple acyl-CoA dehydrogenase deficiency].","date":"2018","source":"Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/30022752","citation_count":4,"is_preprint":false},{"pmid":"34819910","id":"PMC_34819910","title":"Clinical Presentations and Genetic Characteristics of Late-Onset MADD Due to ETFDH Mutations in Five Patients: A Case Series.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34819910","citation_count":4,"is_preprint":false},{"pmid":"10444348","id":"PMC_10444348","title":"Assignment of electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO) to human chromosome 4q33 by fluorescence in situ hybridization and somatic cell hybridization.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10444348","citation_count":4,"is_preprint":false},{"pmid":"39273584","id":"PMC_39273584","title":"Deep Intronic ETFDH Variants Represent a Recurrent Pathogenic Event in Multiple Acyl-CoA Dehydrogenase Deficiency.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39273584","citation_count":3,"is_preprint":false},{"pmid":"32064983","id":"PMC_32064983","title":"Skin damage in a patient with lipid storage myopathy with a novel ETFDH mutation responsive to riboflavin.","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32064983","citation_count":3,"is_preprint":false},{"pmid":"28899466","id":"PMC_28899466","title":"[Clinical features and ETFDH mutations of children with late-onset glutaric aciduria type II: a report of two cases].","date":"2017","source":"Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/28899466","citation_count":3,"is_preprint":false},{"pmid":"33383363","id":"PMC_33383363","title":"Late-onset MADD in Yemen caused by a novel ETFDH mutation misdiagnosed as ADEM.","date":"2020","source":"Multiple sclerosis and related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/33383363","citation_count":3,"is_preprint":false},{"pmid":"40533849","id":"PMC_40533849","title":"The difference of variation types between late-onset multiple acyl-CoA dehydrogenase deficiency patients carrying biallelic and single heterozygous variations in ETFDH: a systematic review and meta-analysis.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40533849","citation_count":2,"is_preprint":false},{"pmid":"36683804","id":"PMC_36683804","title":"Case report: A novel c.1842_1845dup mutation of ETFDH in two Chinese siblings with multiple acyl-CoA dehydrogenase deficiency.","date":"2023","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36683804","citation_count":2,"is_preprint":false},{"pmid":"28851284","id":"PMC_28851284","title":"Anesthetic management of a pediatric patient with Electron Transfer Flavoprotein Dehydrogenase deficiency (ETFDH) and acute appendicitis: case report and review of the literature.","date":"2017","source":"BMC anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/28851284","citation_count":2,"is_preprint":false},{"pmid":"36064718","id":"PMC_36064718","title":"A fatal case of neonatal onset multiple acyl-CoA dehydrogenase deficiency caused by novel mutation of ETFDH gene: case report.","date":"2022","source":"Italian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36064718","citation_count":2,"is_preprint":false},{"pmid":"36779069","id":"PMC_36779069","title":"Case report: Novel ETFDH compound heterozygous mutations identified in a patient with late-onset glutaric aciduria type II.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36779069","citation_count":2,"is_preprint":false},{"pmid":"36588907","id":"PMC_36588907","title":"Lipid storage myopathy due to late-onset multiple Acyl-CoA dehydrogenase deficiency with novel mutations in ETFDH: A case report.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36588907","citation_count":2,"is_preprint":false},{"pmid":"39455656","id":"PMC_39455656","title":"ETFDH mutation involves excessive apoptosis and neurite outgrowth defect via Bcl2 pathway.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39455656","citation_count":1,"is_preprint":false},{"pmid":"31598946","id":"PMC_31598946","title":"[Analysis of ETFDH gene variation in a Chinese family affected with lipid storage myopathy].","date":"2019","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31598946","citation_count":1,"is_preprint":false},{"pmid":"38967380","id":"PMC_38967380","title":"A compound heterozygote case of glutaric aciduria type II in a patient carrying a novel candidate variant in ETFDH gene: A case report and literature review on compound heterozygote cases.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38967380","citation_count":0,"is_preprint":false},{"pmid":"40046021","id":"PMC_40046021","title":"A novel ETFDH mutation identified in a patient with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.","date":"2025","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/40046021","citation_count":0,"is_preprint":false},{"pmid":"39156098","id":"PMC_39156098","title":"Fatal multiple acyl-CoA dehydrogenase deficiency caused by ETFDH gene mutation: A case report.","date":"2024","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/39156098","citation_count":0,"is_preprint":false},{"pmid":"40075430","id":"PMC_40075430","title":"Identification of ETFDH gene c. 487 + 2 T > A pathogenic variant and mechanisms for polycystic kidney in neonatal onset MADD.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40075430","citation_count":0,"is_preprint":false},{"pmid":"42239388","id":"PMC_42239388","title":"Exercise based Intervention For Metabolic Inflexibility Linked With Lipid Storage Myopathy Using Innovative CRISPR Etf-QO Mutant Knock-in Models.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/42239388","citation_count":0,"is_preprint":false},{"pmid":"36162333","id":"PMC_36162333","title":"Generation of a human induced pluripotent stem cell line (LZUSHi002-A) from a MADD patient with ETFDH mutation.","date":"2022","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36162333","citation_count":0,"is_preprint":false},{"pmid":"42231330","id":"PMC_42231330","title":"Genotype-environment interaction drives the onset of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency in carriers of single heterozygous ETFDH variants.","date":"2026","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/42231330","citation_count":0,"is_preprint":false},{"pmid":"42216180","id":"PMC_42216180","title":"Splicing defect and functional characterization of the ETFDH c.1049G > A VUS underlying transient MADD: an iPSC and minigene study.","date":"2026","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/42216180","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.03.25321546","title":"Genomic Modifiers of Neurological Resilience in a Niemann-Pick C family","date":"2025-03-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.03.25321546","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.25.620155","title":"Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics","date":"2024-10-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.25.620155","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32775,"output_tokens":5218,"usd":0.088298,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13802,"output_tokens":3323,"usd":0.076042,"stage2_stop_reason":"end_turn"},"total_usd":0.16434,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"ETF-QO (ETFDH) contains a single [4Fe-4S]2+,1+ cluster and one equivalent of FAD. Site-directed mutagenesis of residues Y501 and T525 (equivalent to Y533 and T558 in porcine ETF-QO) near the iron-sulfur cluster demonstrated that these residues are within hydrogen-bonding distance of cysteine ligands. Single mutations Y501F and T525A decreased the midpoint potential of the iron-sulfur cluster from +37 mV (wild-type) to -60 mV, and the double mutant Y501F/T525A to -128 mV. Lowering the midpoint potential decreased steady-state ubiquinone reductase activity and ETF semiquinone disproportionation, demonstrating that reduction of the iron-sulfur cluster is required for catalytic activity.\",\n      \"method\": \"Site-directed mutagenesis, potentiometric titrations monitored by CW EPR, steady-state ubiquinone reductase activity assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with site-directed mutagenesis and multiple orthogonal assays (EPR, potentiometry, activity) in a single rigorous study\",\n      \"pmids\": [\"18069858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Electron spin relaxation enhancement measurements established that the point-dipole interspin distance between the [4Fe-4S]+ cluster and the FAD semiquinone in ETF-QO is 18.6 ± 1 Å in human, porcine, and Rhodobacter sphaeroides ETF-QO, consistent with the value calculated from the crystal structure of porcine ETF-QO, confirming proximity of the two redox cofactors within the enzyme.\",\n      \"method\": \"Electron spin relaxation enhancement (inversion recovery EPR) on redox-poised proteins; comparison with crystal structure distances\",\n      \"journal\": \"Journal of magnetic resonance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative distance measurement by EPR relaxation enhancement validated against crystal structure, performed across three species independently\",\n      \"pmids\": [\"18037314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutations in ETFDH cause a secondary deficiency of coenzyme Q10 (CoQ10) in skeletal muscle. Patients with ETFDH mutations showed severely decreased respiratory chain complex I and II+III activities and significantly reduced muscle CoQ10, establishing that ETFDH deficiency leads to secondary CoQ10 deficiency and that late-onset glutaric aciduria type II and myopathic CoQ10 deficiency are allelic disorders.\",\n      \"method\": \"Biochemical measurement of CoQ10 and respiratory chain complexes in muscle homogenates; ETFDH gene sequencing; tandem mass spectrometry\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical measurements in patient muscle with genetic confirmation, single cohort study\",\n      \"pmids\": [\"17412732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutations in ETFDH (encoding ETF:QO) cause riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency (RR-MADD). In one patient, ETF:QO mutations were associated with riboflavin-sensitive impairment of ETF:QO activity, and partial deficiencies of flavin-dependent acyl-CoA dehydrogenases and respiratory chain complexes were restored to control levels after riboflavin treatment, indicating that FAD cofactor availability modulates ETF:QO function.\",\n      \"method\": \"ETF:QO enzyme activity assay before and after riboflavin treatment; biochemical analysis of acyl-CoA dehydrogenase and respiratory chain complex activities; ETFDH sequencing\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzyme activity measurements with treatment intervention, single patient with biochemical follow-up\",\n      \"pmids\": [\"17584774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Riboflavin responsiveness in MADD patients with ETF-QO variants is mechanistically explained by a chaperone effect of FAD/riboflavin on variant ETF-QO folding. Variant ETF-QO proteins associated with RR-MADD showed milder folding defects correctable by riboflavin, while non-responsive variants caused severe misfolding. Variant ETF-QO proteins showed prolonged association with the Hsp60 chaperonin in the mitochondrial matrix, and increased cellular peroxide production, indicating that structurally defective ETF-QO leaks electrons and generates reactive oxygen species.\",\n      \"method\": \"HEK-293 cell expression system; steady-state protein level analysis; ETF-QO activity assay; thermal stability measurements; cellular peroxide production assay; Hsp60 co-immunoprecipitation\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (activity assay, thermal stability, co-IP with chaperone, ROS measurement) in a single study with patient-variant correlation\",\n      \"pmids\": [\"22611163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The ETFDH c.158A>G variant causes exon skipping rather than a missense substitution. RNA pull-down of nuclear proteins showed that the variant increases the strength of a preexisting exonic splicing silencer (ESS) motif UAGGGA, which binds inhibitory hnRNP A1, hnRNP A2/B1, and hnRNP H proteins, preventing binding of positive splicing regulators SRSF1 and SRSF5 to overlapping exonic splicing enhancer elements, thereby causing exon 2 skipping and ETFDH protein degradation.\",\n      \"method\": \"Splicing reporter minigenes; RNA pull-down with nuclear proteins; patient sample mRNA analysis; protein identification of binding partners\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — minigene functional assay plus RNA pull-down identifying specific protein-RNA interactions, mechanistically explaining splicing outcome\",\n      \"pmids\": [\"24123825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FAD homeostasis disturbance is a crucial pathomechanism of RR-MADD. In Etfdh knock-in mice (carrying the p.A84T mutation) subjected to high-fat, riboflavin-deficient diet, both ETF:QO protein and FAD concentrations were significantly decreased in tissues. After riboflavin treatment, ETF:QO protein increased in proportion to elevated FAD concentrations but not to mRNA levels, demonstrating that riboflavin stabilizes variant ETF:QO protein post-translationally by rebuilding FAD homeostasis.\",\n      \"method\": \"Etfdh knock-in mouse model; FAD concentration measurements; Western blot; mRNA quantification; patient fibroblast validation\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knock-in mouse model with biochemical and molecular readouts, confirmed in patient fibroblasts, multiple orthogonal methods\",\n      \"pmids\": [\"30232818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ETF-QO (ETFDH gene product) is a nuclear-encoded protein located in the inner mitochondrial membrane. The ETF-QO gene was mapped to human chromosome 4q33 by somatic cell hybridization and fluorescence in situ hybridization.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH); somatic cell hybridization\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal cytogenetic methods for chromosomal localization, single study\",\n      \"pmids\": [\"10444348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ETFDH c.250G>A and c.92C>T mutations in ETF-QO uncouple fatty acid β-oxidation from mitochondrial bioenergetics, resulting in decreased ATP synthesis, dissipated mitochondrial membrane potentials, reduced mitochondrial bioenergetics, and increased neutral lipid droplets and lipid peroxides in MADD patient-derived lymphoblastoid cells. Riboflavin and/or coenzyme Q10 supplementation rescued cells from lipid droplet accumulation.\",\n      \"method\": \"Patient-derived lymphoblastoid cells; ATP synthesis assay; mitochondrial membrane potential measurement; lipid droplet quantification; lipid peroxide assay; pharmacological rescue with riboflavin/CoQ10\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple bioenergetic readouts in patient-derived cells with pharmacological rescue, single lab study\",\n      \"pmids\": [\"30709034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ETFDH p.Ala84Thr mutation increases ROS production and causes neurite shortening in cells expressing the mutant protein. Suberic acid (an accumulated intermediate metabolite in MADD) significantly impairs neurite outgrowth of NSC34 cells. Supplementation with carnitine, riboflavin, or CoQ10 restores neurite length, suggesting that ETF-QO dysfunction causes neuronal defects mediated by metabolic intermediates and oxidative stress.\",\n      \"method\": \"Cell expression system (ETFDH wild-type vs. mutant); ROS production assay; neurite length measurement; pharmacological rescue\",\n      \"journal\": \"Muscle & nerve\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular model with multiple readouts (ROS, neurite length) and pharmacological rescue, single lab\",\n      \"pmids\": [\"27935074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A novel ETFDH c.725C>T (p.T242I) mutation enhances degradation of ETF-QO via the ubiquitin proteasome pathway. Five E3 ubiquitin ligases (STUB1, RNF40, UBE3C, CUL3, and CUL1) and one ubiquitin modification site (Cysteine C101) on ETF-QO were identified.\",\n      \"method\": \"Molecular analysis of ETFDH variant; ubiquitin proteasome pathway assay; identification of E3 ligases and ubiquitination site\",\n      \"journal\": \"Clinica chimica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — identified ubiquitin pathway and specific E3 ligases/modification site, but single lab with limited replication\",\n      \"pmids\": [\"35314173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ETFDH p.Ala84Thr mutation activates the BCL-2/mitochondrial outer membrane permeabilization/apoptosis pathway in NSC-34 cells, as shown by elevated levels of BAX, PUMA, cytochrome c, caspase-3, and caspase-9. CoQ10 treatment downregulated these proapoptotic proteins and mitigated neurite growth defects.\",\n      \"method\": \"NSC-34 cell expression model; Western blot for BCL-2 family proteins; cytochrome c and caspase activity measurement; neurite length assay; pharmacological rescue with CoQ10\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple protein markers of apoptosis pathway quantified with pharmacological rescue, single lab\",\n      \"pmids\": [\"39455656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Elevated muscle CoQ10 in riboflavin-responsive MADD patients with ETFDH mutations is not due to primary CoQ10 biosynthesis dysregulation but rather secondary to mitochondrial mass proliferation. When CoQ10 levels were normalized to citrate synthase (a mitochondrial mass marker), there was no significant difference from controls. Increased mitochondrial DNA copy number confirmed mitochondrial proliferation. PPARα and lipid metabolism genes were upregulated.\",\n      \"method\": \"HPLC measurement of CoQ10 in muscle; citrate synthase normalization; mitochondrial DNA copy number quantification; CoQ10 biosynthesis gene expression analysis; PPARα expression\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical methods in a large patient cohort (34 patients), single lab\",\n      \"pmids\": [\"23628458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ETFDH c.579A>G, a synonymous variant, causes exon 5 skipping. Transcript analysis in vivo and minigene splice assay in vitro confirmed that this synonymous change disrupts normal ETFDH mRNA splicing, leading to production of a truncated protein.\",\n      \"method\": \"In vivo transcript analysis; in vitro minigene splice assay; RT-PCR\",\n      \"journal\": \"Frontiers in pediatrics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional splicing confirmed by two orthogonal methods (in vivo and in vitro minigene), single lab\",\n      \"pmids\": [\"32292771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ETFDH c.487+2T>A mutation leads to mRNA degradation through nonsense-mediated decay (NMD), confirmed by minigene splice assay and RT-PCR. Downregulation of ETFDH in cell experiments led to lipid accumulation, enhanced oxidative stress, and upregulation of ZNF267 expression, suggesting ETFDH is a key regulatory gene in lipid homeostasis and potentially in polycystic kidney development.\",\n      \"method\": \"Minigene splice assay; RT-PCR; in vitro cell knockdown experiments; lipid accumulation assay; oxidative stress measurement; ZNF267 expression analysis\",\n      \"journal\": \"Orphanet journal of rare diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — NMD mechanism confirmed by two orthogonal methods, downstream cellular consequences assessed in vitro, single lab\",\n      \"pmids\": [\"40075430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ETFDH c.1049G>A causes predominant exon 9 skipping resulting in an in-frame 48-amino acid deletion within the FAD-binding domain, confirmed by patient-derived iPSCs and minigene assays. Structural modeling based on the human ETFDH crystal structure showed this deletion disrupts the stabilizing interaction between Arg364 and Glu246, predicting compromised FAD binding. Western blot showed markedly reduced ETFDH protein levels (<10%) in patient cells.\",\n      \"method\": \"iPSC-derived patient cells; minigene splice assay; RT-PCR; structural modeling based on crystal structure; Western blot\",\n      \"journal\": \"Orphanet journal of rare diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — splicing confirmed by two orthogonal functional methods with structural modeling validation, single lab\",\n      \"pmids\": [\"42216180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A splice site ETFDH mutation (c.1285+1G>A, intron 10) alters ETFDH RNA splicing as confirmed by RT-PCR, leading to production of a truncated protein. In silico structural analysis showed the associated missense mutation (c.560C>T) causes instability and loss of protein activation, while the splice variant induces a dramatic conformational change. Patients with at least one missense mutation in the FAD-binding domain may respond to riboflavin or carnitine due to recovery of some enzymatic activity.\",\n      \"method\": \"RT-PCR for splicing analysis; in silico 3D structural prediction of ETF-QO\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — RT-PCR splicing confirmation is solid but structural conclusions rely solely on in silico modeling, single case\",\n      \"pmids\": [\"30424791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In Drosophila CRISPR knock-in models carrying patient-relevant Etf-QO missense mutations in FAD- and ubiquinone-binding domains, defective Etf-QO activity disrupts electron flow, promotes ROS production, impairs fatty acid β-oxidation, causes lipid droplet accumulation in skeletal muscle and cardiac tissue, reduces mitochondrial oxygen consumption, and leads to metabolic cardiomyopathy. Activation of AMPK, PGC-1α, and Tfam indicates compensatory mitochondrial biogenesis in response to energy stress.\",\n      \"method\": \"CRISPR/Cas9 Drosophila knock-in models; locomotor assays; cardiac functional analysis; lipid droplet quantification; in vivo respirometry; ROS measurement; ATP quantification; Western blot for energy stress markers\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR in vivo model with multiple orthogonal functional readouts, preprint not yet peer-reviewed\",\n      \"pmids\": [\"42239388\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ETFDH downregulation in cancer cells (NALM-6 acute lymphoblastic leukemia) limits flexibility of OXPHOS fuel utilization but paradoxically increases cancer cell bioenergetics and accelerates neoplastic growth by activation of the mTORC1/BCL-6/4E-BP1 signaling axis.\",\n      \"method\": \"ETFDH knockdown/knockout in cancer cell lines; bioenergetic profiling; mTORC1/BCL-6/4E-BP1 signaling pathway analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, mechanistic pathway activation described but limited methodological detail in abstract\",\n      \"pmids\": [\"bio_10.1101_2024.10.25.620155\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ETFDH encodes ETF-ubiquinone oxidoreductase (ETF-QO), an inner mitochondrial membrane iron-sulfur flavoprotein that accepts electrons from ETF (and thus from multiple acyl-CoA dehydrogenases involved in fatty acid, amino acid, and choline catabolism) and reduces ubiquinone in the respiratory chain via sequential electron transfer through its [4Fe-4S]2+/1+ cluster (whose midpoint potential is essential for activity) and FAD cofactor, which are positioned ~18.6 Å apart; pathogenic ETFDH mutations impair FAD binding and protein folding (correctable by riboflavin acting as a pharmacological chaperone by restoring FAD homeostasis), cause secondary ROS production, activate apoptotic BCL-2 pathways, and lead to secondary CoQ10 deficiency and lipid accumulation, manifesting as multiple acyl-CoA dehydrogenase deficiency (MADD/glutaric aciduria type II).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ETFDH encodes ETF-ubiquinone oxidoreductase (ETF-QO), a nuclear-encoded iron-sulfur flavoprotein of the inner mitochondrial membrane that channels electrons from electron-transfer flavoprotein into the respiratory chain by reducing ubiquinone, thereby linking fatty acid β-oxidation to mitochondrial bioenergetics [#7, #8]. Catalysis proceeds by sequential electron transfer through a single [4Fe-4S] cluster and an FAD cofactor positioned ~18.6 Å apart, and reduction of the iron-sulfur cluster is obligatory for ubiquinone reductase activity: lowering its midpoint potential through mutation of cluster-proximal residues impairs both ubiquinone reduction and ETF semiquinone disproportionation [#0, #1]. Pathogenic ETFDH mutations destabilize the protein and compromise FAD binding, with riboflavin acting as a pharmacological chaperone that post-translationally stabilizes variant ETF-QO by restoring FAD homeostasis rather than altering transcript levels [#4, #6, #15]. Defective ETF-QO uncouples β-oxidation from ATP synthesis, producing reactive oxygen species, lipid droplet accumulation, secondary CoQ10 deficiency, and activation of BCL-2/mitochondrial apoptotic signaling, the molecular basis of multiple acyl-CoA dehydrogenase deficiency (MADD/glutaric aciduria type II) [#2, #8, #11]. A substantial fraction of disease alleles act not as simple missense changes but by disrupting splicing — strengthening exonic silencers, causing exon skipping, or triggering nonsense-mediated decay — and unstable variants are additionally cleared through the ubiquitin-proteasome pathway [#5, #10, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing that ETF-QO is a nuclear-encoded inner mitochondrial membrane protein and mapping its gene provided the genetic and subcellular framework for all subsequent disease and mechanistic work.\",\n      \"evidence\": \"FISH and somatic cell hybridization localizing ETFDH to chromosome 4q33\",\n      \"pmids\": [\"10444348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not address catalytic mechanism or cofactor content\", \"No functional characterization of the protein\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Quantifying the geometry of the two redox cofactors and demonstrating that iron-sulfur cluster reduction is required for catalysis defined the electron-transfer mechanism of ETF-QO.\",\n      \"evidence\": \"EPR relaxation-enhancement interspin distance measurement across three species plus site-directed mutagenesis with potentiometric and activity assays\",\n      \"pmids\": [\"18037314\", \"18069858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mutated residues are model probes, not necessarily disease alleles\", \"Did not resolve how ETF docks and delivers electrons\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linking ETFDH mutations to secondary CoQ10 deficiency and riboflavin-responsive MADD connected enzyme dysfunction to defined clinical metabolic phenotypes and a treatment.\",\n      \"evidence\": \"Patient muscle biochemistry, respiratory chain and ETF-QO activity assays before/after riboflavin, with ETFDH sequencing\",\n      \"pmids\": [\"17412732\", \"17584774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of riboflavin responsiveness unresolved at this stage\", \"Single-cohort/single-patient observations\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that RR-MADD variants are folding-defective and stabilized by FAD/riboflavin established a chaperone mechanism for riboflavin therapy and connected misfolding to ROS leakage.\",\n      \"evidence\": \"HEK-293 expression of variants with thermal stability, activity, Hsp60 co-IP, and cellular peroxide assays\",\n      \"pmids\": [\"22611163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hsp60 association shown by co-IP without reciprocal/structural validation\", \"Did not quantify FAD occupancy directly\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating in vivo that riboflavin raises variant ETF-QO protein in proportion to FAD but not mRNA confirmed FAD homeostasis as the post-translational basis of riboflavin rescue.\",\n      \"evidence\": \"Etfdh p.A84T knock-in mouse on high-fat/riboflavin-deficient diet with FAD measurement, Western blot, mRNA quantification, and patient fibroblast validation\",\n      \"pmids\": [\"30232818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single mutation knock-in\", \"Did not map FAD-binding kinetics of individual variants\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defining how ETF-QO mutations uncouple β-oxidation from bioenergetics and drive lipid accumulation clarified the downstream cellular pathology of MADD and the basis for CoQ10 supplementation.\",\n      \"evidence\": \"Patient lymphoblastoid cells with ATP synthesis, membrane potential, lipid droplet and peroxide assays plus riboflavin/CoQ10 rescue\",\n      \"pmids\": [\"30709034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lymphoblastoid model not tissue-specific\", \"Did not separate direct enzyme loss from secondary CoQ10 deficiency\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying activation of the BCL-2/MOMP apoptotic cascade in mutant-expressing neuronal cells linked ETF-QO dysfunction to a defined cell-death program reversible by CoQ10.\",\n      \"evidence\": \"NSC-34 expression model with Western blot for BAX/PUMA/cytochrome c/caspases, ROS and neurite assays with CoQ10 rescue\",\n      \"pmids\": [\"39455656\", \"27935074\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression model in a single neuronal line\", \"Causal ordering of ROS, apoptosis, and metabolite toxicity not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Characterizing splicing-disrupting and proteasome-degraded alleles revealed that ETFDH disease is frequently driven by transcript and protein turnover defects rather than missense catalytic loss alone.\",\n      \"evidence\": \"Minigene splice assays, RNA pull-down identifying hnRNP/SRSF regulators, RT-PCR, NMD analysis, and ubiquitin-proteasome assays identifying E3 ligases and a ubiquitination site\",\n      \"pmids\": [\"24123825\", \"32292771\", \"35314173\", \"40075430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase set identified in a single study without in vivo validation\", \"ZNF267/polycystic kidney link is correlative\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Structure-guided modeling of an in-frame FAD-domain deletion and in vivo Drosophila knock-in models connected specific structural lesions to FAD-binding loss, cardiac and muscle lipid pathology, and compensatory mitochondrial biogenesis.\",\n      \"evidence\": \"Patient iPSCs with minigene/RT-PCR and crystal-structure-based modeling; CRISPR Drosophila knock-ins with respirometry, lipid, ROS and energy-stress marker assays (one preprint)\",\n      \"pmids\": [\"42216180\", \"42239388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Drosophila findings are a non-peer-reviewed preprint\", \"Structural consequence of the deletion is modeled, not experimentally resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of human ETF-QO in complex with ETF and ubiquinone, and a unified model relating individual variant cofactor occupancy to clinical riboflavin responsiveness, remain to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No experimental human ETF-QO/ETF complex structure in the corpus\", \"No systematic variant-by-variant FAD-occupancy/responsiveness map\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0009055\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005743\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [7, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 2]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ETF\", \"Hsp60\", \"STUB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":5,"faith_pct":100.0}}